Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Pediatrics
Published in: European Journal of Pediatrics 10/2016

01-10-2016 | Review

Probiotic supplementation in children with cystic fibrosis—a systematic review

Authors: Anitha Ananthan, Haribalakrishna Balasubramanian, Shripada Rao, Sanjay Patole

Published in: European Journal of Pediatrics | Issue 10/2016

Login to get access

Abstract

Probiotics may benefit in cystic fibrosis (CF) as gut dysbiosis is associated with gastrointestinal symptoms and exacerbation of respiratory symptoms in CF. We conducted a systematic review of randomized controlled trials (RCTs) and non-RCTs of probiotic supplementation in children with CF, using the Cochrane methodology, preferred reporting items for systematic reviews (PRISMA) statement, and meta-analysis of observational studies in epidemiology (MOOSE) guidelines. Primary outcomes were pulmonary exacerbations, duration of hospitalization and antibiotics, and all-cause mortality. Secondary outcomes included gastrointestinal symptoms, markers of gut inflammation, and intestinal microbial balance. A total of nine studies (RCTs, 6, non-RCTs, 3; N = 275) with some methodological weaknesses were included in the review. The pooled estimate showed significant reduction in the rate of pulmonary exacerbation (fixed effects model, two parallel group RCTs and one cross-over trial: relative risk (RR) 0.25, (95 % confidence interval (95 % CI) 0.15,0.41); p < 0.00001; level of evidence: low) and decrease in fecal calprotectin (FCLP) levels (fixed effect model, three RCTs: mean difference (MD) −16.71, 95 % CI −27.30,−6.13); p = 0.002; level of evidence: low) after probiotic supplementation. Probiotic supplementation significantly improved gastrointestinal symptoms (one RCT, one non-RCT) and gut microbial balance (decreased Proteobacteria, increased Firmicutes, and Bacteroides in one RCT, one non-RCT).
Conclusion: Limited low-quality evidence exists on the effects of probiotics in children with CF. Well-designed adequately powered RCTs assessing clinically meaningful outcomes are required to study this important issue.
What is Known:
• Gut dysbiosis is frequent in children with cystic fibrosis due to frequent exposure to pathogens and antibiotics.
• Probiotics decrease gut dysbiosis and improve gut maturity and function.
What is New:
• This comprehensive systematic review shows that current evidence on the safety and efficacy of probiotics in children with cystic fibrosis is limited and of low quality.
• Well-designed and adequately powered trials assessing clinically important outcomes are required considering the health burden of cystic fibrosis and the potential benefits of probiotics.
Literature
1.
2.
Bermudez-Brito M, Plaza-Diaz J, Munoz-Quezada S, Gomez-Llorente C, Gil A (2012) Probiotic mechanisms of action. Ann Nutr Metab 61(2):160–174CrossRefPubMed
3.
Borowitz D, Gelfond D (2013) Intestinal complications of cystic fibrosis. Curr Opin Pulm Med 19(6):676–680CrossRefPubMed
4.
5.
Bruzzese E, Raia V, Gaudiello G, Polito G, Buccigrossi V, Formicola V, Guarino A (2004) Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther 20(7):813–819CrossRefPubMed
6.
Bruzzese E, Raia V, Spagnuolo MI, Volpicelli M, De Marco G, Maiuri L, Guarino A (2007) Effect of lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Clin Nutr (Edinburgh, Scotland) 26(3):322–328CrossRef
7.
Bruzzese E, Callegari ML, Raia V, Viscovo S, Scotto R, Ferrari S, Morelli L, Buccigrossi V, Lo Vecchio A, Ruberto E, Guarino A (2014) Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial. PLoS One 9(2):e87796. doi:10.​1371/​journal.​pone.​0087796 CrossRefPubMedPubMedCentral
8.
Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE (2001) Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 33(1):14–22CrossRefPubMed
9.
Canani RB, Cirillo P, Bruzzese E, Graf M, Terrin G, Gaudiello G, De Curtis M, Cucchiara S, Guarino A (2002) Nitric oxide production in rectal dialysate is a marker of disease activity and location in children with inflammatory bowel disease. Am J Gastroenterol 97(6):1574–1576. doi:10.​1111/​j.​1572-0241.​2002.​05757.​x CrossRefPubMed
10.
Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, Cosenza L, Staiano A, Troncone R (2008) Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 40(7):547–553. doi:10.​1016/​j.​dld.​2008.​01.​017 CrossRefPubMed
11.
Chapman CM, Gibson GR, Rowland I (2011) Health benefits of probiotics: are mixtures more effective than single strains? Eur J Nutr 50(1):1–17CrossRefPubMed
12.
Croft NM, Marshall TG, Ferguson A (1995) Gut inflammation in children with cystic fibrosis on high-dose enzyme supplements. Lancet 346(8985):1265–1267CrossRefPubMed
13.
Cystic Fibrosis Foundation (1994) Mycrobiology and infectious disease in cystic fibrosis. Consensus conferences: concept in care. Bethesda Vol V, sect
14.
Dagli E, Warner JA, Besley CR, Warner JO (1992) Raised serum soluble interleukin-2 receptor concentrations in cystic fibrosis patients with and without evidence of lung disease. Arch Dis Child 67(4):479–481CrossRefPubMedPubMedCentral
15.
De Vos M, Louis EJ, Jahnsen J, Vandervoort JG, Noman M, Dewit O, D’Haens GR, Franchimont D, Baert FJ, Torp RA, Henriksen M, Potvin PM, Van Hootegem PP, Hindryckx PM, Moreels TG, Collard A, Karlsen LN, Kittang E, Lambrecht G, Grimstad T, Koch J, Lygren I, Coche JC, Mana F, Van Gossum A, Belaiche J, Cool MR, Fontaine F, Maisin JM, Muls V, Neuville B, Staessen DA, Van Assche GA, de Lange T, Solberg IC, Vander Cruyssen BJ, Vermeire SA (2013) Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 19(10):2111–2117CrossRefPubMed
16.
del Campo R, Garriga M, Perez-Aragon A, Guallarte P, Lamas A, Maiz L, Bayon C, Roy G, Canton R, Zamora J, Baquero F, Suarez L (2014) Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: a double blind prospective study. J Cyst Fibros 13(6):716–722CrossRefPubMed
17.
Di Benedetto LRV, Pastore A, Albano F, Spagnuolo MI, DeVizia B, Guarino A (1998) Lactobacillus casei strain GG as adjunctive treatment to children with cystic fibrosis. J Pediatr Gastroenterol Nutr 26(5):542CrossRef
18.
Di Nardo G, Oliva S, Menichella A, Pistelli R, De Biase RV, Patriarchi F, Cucchiara S, Stronati L (2014) Lactobacillus reuteri ATCC55730 in cystic fibrosis. J Pediatr Gastroenterol Nutr 58(1):81–86CrossRefPubMed
19.
Duytschaever G, Huys G, Bekaert M, Boulanger L, De Boeck K, Vandamme P (2011) Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings. Appl Environ Microbiol 77(22):8015–8024CrossRefPubMedPubMedCentral
20.
Duytschaever G, Huys G, Bekaert M, Boulanger L, De Boeck K, Vandamme P (2013) Dysbiosis of Bifidobacteria and Clostridium cluster XIVa in the cystic fibrosis fecal microbiota. J Cystic Fibros 12(3):206–215CrossRef
21.
Eren Z, Gurol Y, Sonmezoglu M, Eren HS, Celik G, Kantarci G (2014) Saccharomyces cerevisiae fungemia in an elderly patient following probiotic treatment. Mikrobiyoloji bulteni 48(2):351–355CrossRefPubMed
22.
Fagerberg UL, Loof L, Merzoug RD, Hansson LO, Finkel Y (2003) Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr 37(4):468–472CrossRefPubMed
23.
Fallahi G, Motamed F, Yousefi A, Shafieyoun A, Najafi M, Khodadad A, Farhmand F, Ahmadvand A, Rezaei N (2013) The effect of probiotics on fecal calprotectin in patients with cystic fibrosis. Turk J Pediatr 55(5):475–478PubMed
24.
Franko B, Vaillant M, Recule C, Vautrin E, Brion JP, Pavese P (2013) Lactobacillus paracasei endocarditis in a consumer of probiotics. Medecine et maladies infectieuses 43(4):171–173CrossRefPubMed
25.
Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, Gisbert JP, Gallardo-Valverde JM, Gonzalez-Galilea A, Naranjo-Rodriguez A, de Dios-Vega JF, Muntane J, Gomez-Camacho F (2010) Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohn’s Colitis 4(2):144–152CrossRef
26.
M. Garriga AdB, M. Burreros, P. Guallarte, A. Perez-Aragon, A. Lamas, del Campo R., L. Suarez (2013) Probiotic intake improves the gastrointestinal health of cystic fibrosis patients. Paper presented at the J Cyst Fibros
27.
Ghadimi D, Vrese M, Heller KJ, Schrezenmeir J (2010) Effect of natural commensal-origin DNA on toll-like receptor 9 (TLR9) signaling cascade, chemokine IL-8 expression, and barrier integritiy of polarized intestinal epithelial cells. Inflamm Bowel Dis 16(3):410–427CrossRefPubMed
28.
Gillanders LEJ, Gilpin D, Schneiders T, Tunney MT (2011) The airway microbiome in cystic fibrosis: challenges for therapy. Therapy 8(645e):60
29.
Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119(2):305–309CrossRefPubMed
30.
Grimoud J, Durand H, de Souza S, Monsan P, Ouarne F, Theodorou V, Roques C (2010) In vitro screening of probiotics and synbiotics according to anti-inflammatory and anti-proliferative effects. Int J Food Microbiol 144(1):42–50CrossRefPubMed
31.
Guarino A (2015) Effects of LGG administration in children with cystic fibrosis: a randomized controlled trial. Effects of LGG administration in children with cystic fibrosis: a randomized controlled trial: Federico II University
32.
Guslandi M, Mezzi G, Sorghi M, Testoni PA (2000) Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 45(7):1462–1464CrossRefPubMed
33.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed) 336(7650):924–926CrossRef
34.
Hawrelak JA, Myers SP (2004) The causes of intestinal dysbiosis: a review. Altern med review 9(2):180–197
35.
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clinical researched) 343:d5928. doi:10.​1136/​bmj.​d5928 CrossRef
36.
Hoen AG, Li J, Moulton LA, O’Toole GA, Housman ML, Koestler DC, Guill MF, Moore JH, Hibberd PL, Morrison HG, Sogin ML, Karagas MR, Madan JC (2015) Associations between gut microbial colonization in early life and respiratory outcomes in cystic fibrosis. J Pediatr 167(1):138–147 e131-133CrossRefPubMedPubMedCentral
37.
Iannitti T, Palmieri B (2010) Therapeutical use of probiotic formulations in clinical practice. Clin Nutr (Edinburgh, Scotland) 29(6):701–725CrossRef
38.
Infante Pina D, Redecillas Ferreiro S, Torrent Vernetta A, Segarra Canton O, Maldonado Smith M, Gartner Tizziano L, Hidalgo Albert E (2008) Improvement of intestinal function in cystic fibrosis patients using probiotics. Anales de Pediatria (Barcelona, Spain: 2003) 69(6):501–505CrossRef
39.
40.
Jafari SA, Mehdizadeh-Hakkak A, Kianifar HR, Hebrani P, Ahanchian H, Abbasnejad E (2013) Effects of probiotics on quality of life in children with cystic fibrosis; a randomized controlled trial. Iran J Pediatr 23(6):669–674PubMedPubMedCentral
41.
Jensen H, Dromtorp SM, Axelsson L, Grimmer S (2014) Immunomodulation of monocytes by probiotic and selected lactic acid bacteria. Probiotics Antimicrob Proteins. doi:10.​1007/​s12602-014-9174-2
42.
Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG (2012) The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 46(3):220–227CrossRefPubMed
43.
Kim JY, Kwon JH, Ahn SH, Lee SI, Han YS, Choi YO, Lee SY, Ahn KM, Ji GE (2010) Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. Pediatr. Allerg Immunol 21(2 Pt 2):e386–e393. doi:10.​1111/​j.​1399-3038.​2009.​00958.​x CrossRef
44.
Lasson A, Stotzer PO, Ohman L, Isaksson S, Sapnara M, Strid H (2015) The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohn’s Colitis 9(1):26–32
45.
Li F, Sheng XY (2014) Research advances in the role of fecal calprotectin in intestinal development and diseases among children. Zhongguo dang dai er ke za zhi [Chinese Journal of Contemporary Pediatrics] 16(10):1064–1069
46.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical researched) 339:b2700. doi:10.​1136/​bmj.​b2700 CrossRef
47.
Lin YP, Thibodeaux CH, Pena JA, Ferry GD, Versalovic J (2008) Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis 14(8):1068–1083CrossRefPubMed
48.
Macfarlane GT, Blackett KL, Nakayama T, Steed H, Macfarlane S (2009) The gut microbiota in inflammatory bowel disease. Current Pharmaceutical Design BMJ Open 15(13):1528–1536CrossRef
49.
Navas-Lopez VM, Giron B-AJ, Fernandez-Crehuet F, Serrano Nieto MJ, Vicioso Recio MI, Sierra Salinas C (2013) Intestinal inflammation in cystic fibrosis: lack of effectiveness after treatment with mesalamine and probiotics. In: Ann Nutr Metab. Conference absract: 20th International Congress of Nutrition Granada Spain (63):1694–1695
50.
Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC (2009) Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 15(2):300–310CrossRefPubMed
51.
Olafsdottir E, Aksnes L, Fluge G, Berstad A (2002) Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta paediatrica (Oslo, Norway: 1992) 91(1):45–50CrossRef
52.
53.
54.
55.
Preidis GA, Saulnier DM, Blutt SE, Mistretta TA, Riehle KP, Major AM, Venable SF, Finegold MJ, Petrosino JF, Conner ME, Versalovic J (2012) Probiotics stimulate enterocyte migration and microbial diversity in the neonatal mouse intestine. Gastroenterology 26(5):1960–1969
56.
57.
Sánchez-Calvo JM, Garcia-Castillo M, Lamas A, Rodriguez-Baños M, Máiz L, Suárez L, Baquero F, Canton R, del Campo R (2008) Gut microbiota composition in cystic fibrosis patients: molecular approach and classical culture. J Cyst Fibros 7(Suppl. 2):S50CrossRef
58.
Scotto G (2011) Globalization and infectious diseases: the past and future. Le infezioni in medicina: rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 19(1):56–61
59.
Shoaib A, Dachang W, Xin Y (2015) Determining the role of a probiotic in the restoration of intestinal microbial balance by molecular and cultural techniques. Genet Mol Res: GMR 14(1):1526–1537CrossRefPubMed
60.
61.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008–2012CrossRefPubMed
62.
Summerton CB, Longlands MG, Wiener K, Shreeve DR (2002) Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 14(8):841–845CrossRefPubMed
63.
Tena D, Martinez NM, Losa C, Fernandez C, Medina MJ, Saez-Nieto JA (2013) Acute acalculous cholecystitis complicated with peritonitis caused by lactobacillus plantarum. Diagn Microbiol Infect Dis 76(4):510–512CrossRefPubMed
64.
Tena D, Losa C, Medina MJ, Saez-Nieto JA (2014) Peritonitis caused by Bifidobacterium longum: case report and literature review. Anaerobe 27:27–30CrossRefPubMed
65.
66.
67.
Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW (2009) Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials 30(3):256–268CrossRefPubMedPubMedCentral
68.
Varni JW, Burwinkle TM, Seid M (2006) The PedsQL 4.0 as a school population health measure: feasibility, reliability, and validity. Qual Life Res: an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation 15(2):203–215CrossRef
69.
70.
Weiss B, Bujanover Y, Yahav Y, Vilozni D, Fireman E, Efrati O (2010) Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Pediatr Pulmonol 45(6):536–540PubMed
71.
72.
Werlin SL, Benuri-Silbiger I, Kerem E, Adler SN, Goldin E, Zimmerman J, Malka N, Cohen L, Armoni S, Yatzkan-Israelit Y, Bergwerk A, Aviram M, Bentur L, Mussaffi H, Bjarnasson I, Wilschanski M (2010) Evidence of intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 51(3):304–308. doi:10.​1097/​MPG.​0b013e3181d1b013​ PubMed
73.
Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, Chan HL (2013) Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepato 12(2):256–262
74.
Zein EF, Karaa S, Chemaly A, Saidi I, Daou-Chahine W, Rohban R (2008) Lactobacillus rhamnosus septicemia in a diabetic patient associated with probiotic use: a case report. Ann Biol Clin 66(2):195–198
Metadata
Title
Probiotic supplementation in children with cystic fibrosis—a systematic review
Authors
Anitha Ananthan
Haribalakrishna Balasubramanian
Shripada Rao
Sanjay Patole
Publication date
01-10-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Pediatrics / Issue 10/2016
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-016-2769-8

Other articles of this Issue 10/2016

European Journal of Pediatrics 10/2016 Go to the issue

Original Article

Speckle tracking echocardiography detects decreased cardiac longitudinal function in anthracycline-exposed survivors of childhood cancer

Original Article

Granulocyte transfusions in critically ill children with prolonged neutropenia: side effects and survival rates from a single-center analysis

Review

The association between childcare and risk of childhood overweight and obesity in children aged 5 years and under: a systematic review

Original Article

Screening for autism identifies behavioral disorders in children functional defecation disorders

Original Article

Therapeutic clowns in pediatrics: a systematic review and meta-analysis of randomized controlled trials

Review

Parental views on otitis media: systematic review of qualitative studies